NanoRepro AGXTER:NN6 +12.79%51 Altman Z2-Score is 47.55 as of Jul. 06, 2026, which is 374% above its 10-year median of 10.03. GuruFocus rates XTER:NN6 with a GF Score™ of 51/100 and a GF Value™ of €1.00 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, NanoRepro AG ranks better than 99.53% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
NanoRepro AG has a Altman Z2-Score of 47.55, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for NanoRepro AG's Altman Z2-Score or its related term are showing as below:
XTER:NN6'
s Altman Z2-Score Range Over the Past 10 Years
Min: 0.61 Med: 10.03 Max: 47.55
Current: 47.55
During the past 13 years, NanoRepro AG's highest Altman Z2-Score was 47.55. The lowest was 0.61. And the median was 10.03.
NanoRepro AG (XTER:NN6) Altman Z2-Score Explanation
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
Altman Z2-Score does not apply to financial companies.
NanoRepro AG Altman Z2-Score Related Terms
NanoRepro AG Altman Z2-Score Historical Data
* Premium members only.
The historical data trend for NanoRepro AG's Altman Z2-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:NN6 vs TMO, DHR, IDXX: Altman Z2-Score Comparison
For the Diagnostics & Research subindustry, NanoRepro AG's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NanoRepro AG Altman Z2-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NanoRepro AG's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where NanoRepro AG's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
NanoRepro AG's Altman Z2-Score for today is calculated with this formula:
Z
=
6.56
*
X1
+
3.26
*
X2
+
6.72
*
X3
+
1.05
*
X4_2
=
6.56
*
0.3756
+
3.26
*
0.079
+
6.72
*
-0.0701
+
1.05
*
43.1459
=
47.55
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
NanoRepro AG (XTER:NN6) has a Altman Z2-Score of 47.55 as of Jul. 06, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on NanoRepro AG and its competitors. This is 374% above median its historical median of 10.03. Over the past decade, NanoRepro AG's Altman Z2-Score has ranged from 0.61 to 47.55. According to the industry distribution chart, NanoRepro AG ranks #1 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 0.5%.
Is NanoRepro AG's Altman Z2-Score too high?
NanoRepro AG's current Altman Z2-Score of 47.55 is 374% above median its 10-year median of 10.03. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 47.55. The Medical Diagnostics & Research industry median Altman Z2-Score is 1.80. NanoRepro AG's value of 47.55 is 2549% above this industry median. Based on the distribution chart, NanoRepro AG ranks #1 out of 212 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, NanoRepro AG has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NanoRepro AG's Altman Z2-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, NanoRepro AG ranks #1 out of 212 companies for Altman Z2-Score. This places NanoRepro AG in the top 1% of its industry — outperforming the majority of peers. The industry median Altman Z2-Score is 1.80. NanoRepro AG's value of 47.55 is 2549% above this benchmark. Historically, NanoRepro AG's own Altman Z2-Score has ranged from 0.61 to 47.55 over the past decade. While the company's 10-year median is 10.03 vs. the industry median of 1.80, NanoRepro AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Diagnostics & Research company?
The median Altman Z2-Score among Medical Diagnostics & Research companies is 1.80, based on 212 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NanoRepro AG's current Altman Z2-Score of 47.55 is 2549% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on NanoRepro AG and its competitors. For the Medical Diagnostics & Research industry, the median Altman Z2-Score is 1.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NanoRepro AG's current Altman Z2-Score is 47.55, which is 374% above median its own 10-year median of 10.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NanoRepro AG stock overvalued right now?
Based on GuruFocus' analysis, NanoRepro AG (XTER:NN6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.00, compared to a current price of €2.16 — trading 116% above its estimated fair value. The current Altman Z2-Score is 47.55, which is 374% above median its 10-year median of 10.03 and 2549% above the Medical Diagnostics & Research industry median of 1.80. NanoRepro AG's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For NanoRepro AG (XTER:NN6), the current Altman Z2-Score is 47.55 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NanoRepro AG (XTER:NN6) Overvalued in 2026?
Based on GuruFocus' analysis, NanoRepro AG stock appears to be overvalued.
The current stock price of €2.16 is trading 116% above its estimated GF Value™ of €1.00.
GuruFocus considers NanoRepro AG to be Significantly Overvalued.
Key valuation signals for XTER:NN6:
Altman Z2-Score: 47.55 (374% above median its 10-year median of 10.03)
GF Value™: €1.00 vs. price of €2.16 (116% above fair value)
Industry Position: 2549% above the Medical Diagnostics & Research median (#1 of 212)
No single metric tells the full story. See the XTER:NN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use.
51GF Score
Get the complete analysis for XTER:NN6
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:NN6 has been successfully added to your 
